Receptor activator of nuclear factor kappa B ligand and osteoprotegerin expression in chronic apical periodontitis: Possible association with inflammatory cells

Chinese Medical Journal

Volumn 124, Issue 14, 2011, Pages 2162-2166

  Fan, Rong ^a   Sun, Bin ^b   Zhang, Cheng Fei ^c   Lü, Ya Lin ^a   Xuan, Wei ^a   Wang, Qian Qian ^d   Yin, Xing Zhe ^d  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d PEKING UNIVERSITY   (China)

Author keywords

Apical periodontitis; Bone resorption; Immunohistochemistry; Inflammation; Osteoprotegerin; Receptor activator of nuclear factor kappa B ligand

Indexed keywords

CD20 ANTIGEN; CD3 ANTIGEN; CD68 ANTIGEN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ADOLESCENT; ADULT; ARTICLE; CELL COUNT; CELL INFILTRATION; CONTROLLED STUDY; DISEASE SEVERITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TOOTH PERIAPICAL DISEASE;

EID: 79960684152     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.14.015     Document Type: Article

References (32)

1. Nair PN. Apical periodontitis: a dynamic encounter between root canal infection and host response. Periodontal 2000 1997; 13: 121-148.
2. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000; 289: 1504-1508.
3. Haynes DR, Crotti TN, Loric M, Bain GI, Atkins GJ, Findlay DM. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology 2001; 40: 623-630.
4. Kawai T, Matsuyama T, Hosokawa Y, Makihira S, Seki M, Karimbux NY, et al. B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am J Pathol 2006; 169: 987-998.
5. Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-kappa B ligand and osteoprotegerin in bone cell biology. J Mol Med 2001; 79: 243-253.
6. Geng DC, Xu YZ, Yang HL, Zhu GM, Wang XB, Zhu XS. Cannabinoid receptor-2 selective antagonist negatively regulates receptor activator of nuclear factor kappa B ligand mediated osteoclastogenesis. Chin Med J 2011; 124: 586-590.
7. Arron JR, Choi Y. Bone versus immune system. Nature 2000; 408: 535-536.
8. Sila TA, Garlet GP, Fukada SY, Silva JS, Cunha FQ. Chemokines in oral inflammatory diseases: apical periodontitis and periodontal disease. J Dent Res 2007; 86: 306-319.
9. Liu YC, Lerner UH, Teng YT. Cytokine responses against periodontal infection: protective and destructive roles. Periodontology 2000 2010; 52: 163-206.
10. Sabeti M, Simon V, Kermani Y, Valles Y, Rostein I. Detection of receptor activator of NF-κB ligand in apical periodontitis. J Endod 2005; 31: 17-18.
11. Menezes R, Bramante CM, da Silva Paiva KB, Letra A, Carneiro E, Fernando Zambuzzi W, et al. Receptor activator NFkB-ligand and osteoprotegerin protein expression in human periapical cysts and granulomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 102: 404-409.
12. Matsuo T, Ebisu S, Shimabukuro Y, Ohtake T, Okada H. Quantitative analysis of immunocompetent cells in human periapical lesions: correlations with clinical findings of the involved teeth. J Endod 1992; 18: 497-500.
13. Ihan Hren N, Ihan A. T lymphocyte activation and cytokine expression in periapical granulomas and radicular cysts. Arch Oral Boil 2009; 54: 156-161.
14. Fukada SY, Silva TA, Garlet GP, Rosa AL, da Silva JS, Cunha FQ. Factors involved in the T helper type 1 and type 2 cell commitment and osteoclast regulation in inflammatory apical diseases. Oral Microbiol Immunol 2009; 24: 25-31.
15. Vernal R, Dezerega A, Dutzan N, Chaparro A, León R, Chandía S, et al. RANKL in human periapical granuloma: possible involvement in periapical bone destruction. Oral Dis 2006; 12: 283-289.
16. Kawashima N, Suzuki N, Yang G, Ohi C, Okuhara S, Nakano-Kawanishi H, et al. Kinetics of RANKL, RANK and OPG expressions in experimentally induced rat periapical lesions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 103: 707-711.
17. Hayer S, Polzer K, Brandl A, Zwerina J, Kireva T, Smolen JS, et al. B-cell infiltrates induce endosteal bone formation in inflammatory arthritis. J Bone Miner Res 2008; 23: 1650-1660.
18. Bostanci N, Ilgenli T, Emingil G, Afacan B, Han B, TÖz H, et al. Gingival crevicular fluid levels of RANKL and OPG in periodontol diseases: implications of their relative ratio. J Clin periodontal 2007; 34: 370-376.
19. Tsai CH, Weng SF, Yang LC, Huang FM, Chen YJ, Chang YC. Immunohistochemical localization of tissue-type plasminogen activator and type I plasminogen activator inhibitor in radicular cysts. J Oral Pathol Med 2004; 33: 156-161.
20. Liapatas S, Nakou M, Rontogianni D. Inflammatory infiltrate of chronic periradicular lesions: an immunohistochemical study. Int Endod J 2003; 36: 464-471.
21. Takayanagi H. Inflammatory bone destruction and osteoimmunology. J Periodont Res 2005; 40: 287-293.
22. Choi Y, Woo KM, Ko SH, Lee YJ, Park SJ, Kim HM, et al. Osteoclastogenesis is enhanced by activated B cells but suppressed by activated CD8+ T cells. Eur J Immunol 2001; 31: 2179-2188.
23. + T lymphocytes. J Periodontal 2006; 77: 1772-1780.
24. Crotti T, Smith MD, Hirsch R, Soukoulis S, Weedon H, Capone M, et al. Receptor activator NFκB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis. J Periodontal Res 2003; 38: 380-387.
25. Crotti TN, Smith MD, Findlay DM, Zreiqat H, Ahern MJ, Weedon H, et al. Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NFkB, RANK ligand and osteoprtogerin. Biomateials 2004; 25: 565-573.
26. Metzger Z. Macrophages in periapical lesions. Endod Dent Traumatol 2000; 16: 1-8.
27. Yoshinaga Y, Ukai T, Abe Y, Hara Y. Expression of receptor activator of nuclear factor kappa B ligand relates to inflammatory bone resorption, with or without occlusal truma, in rats. J Periodont Res 2007; 42: 402-409.
28. Horowitz MC, Fretz JA, Lorenzo JA. How B cells influence bone biology in health and disease. Bone 2010; 47: 472-479.
29. Manabe N, Kawaguchi H, Chikuda H, Miyaura C, Inada M, Nagai R, et al. Connection between B lymphocyte and osteoclast differentiation pathways. J Immunol 2001; 167: 2625-2631.
30. Geusens PP, Landewé RBM, Garnero P, Chen D, Dunstan CR, Lems WF, et al. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum 2006; 54: 1772-1777.
31. Jiang J, Li H, Fahid FS, Filbert E, Safavi KE, Spangberg LS, et al. Quantitative analysis of osteoclast-specific gene markers stimulated by lipopolysaccharide. J Endod 2006; 32: 742-746.
32. Menezes R, Garlet TP, Letra A, Bramante CM, Campanelli AP, Figueira Rde C, et al. Differential patterns of receptor activator of nuclear factor kappa B ligand/osteoprotegerin expression in human periapical granulomas: possible association with progressive or stable nature of the lesions. J Endod 2008; 34: 932-938.